Dr. Michael Berendt reports

VETOQUINOL TO ACQUIRE THE ANIMAL HEALTH BUSINESS OF BIONICHE LIFE SCIENCES INC.

Vetoquinol and Bioniche Life Sciences Inc. have signed a share purchase agreement under which Vetoquinol has agreed to purchase Bioniche's animal health business for the cash purchase price of $61-million. This agreement remains subject to approval by shareholders of Bioniche Life Sciences and to the usual closing conditions for a transaction of this type. The boards of directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.

"We look forward to the integration of [the] Bioniche animal health business into our organization," said Vetoquinol's chief executive officer Matthieu Frechin. "This acquisition is a new milestone in the implementation of our long-term strategic plan. It will represent a significant reinforcement of our portfolio of products with immediate synergies in Canada and the United States, and mid-term prospects in other markets."

"In May, 2013, Bioniche Life Sciences began a formal process to divest our animal health business," said Dr. Michael Berendt, CEO of Bioniche Life Sciences. "This divestment is the logical progression of our corporate strategy to create a well-capitalized company focused on human health," added Dr. Berendt. "Our goal is the successful commercialization of our phase 3 bladder cancer therapy, Urocidin, and the addition of another oncology asset to our development pipeline."

The Bioniche animal health divestment process was led by Evercore, a U.S.-based independent advisory firm that specializes in merger and acquisition transactions, divestitures, and restructurings.

About Vetoquinol

Vetoquinol is an independent family-owned business and global player in the animal health sector, serving both the livestock (cattle and swine) and pet (dogs and cats) markets.

Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation and geographical diversification. The group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high-growth markets. Vetoquinol employs over 1,850 people globally. Vetoquinol has been listed on NYSE Euronext Paris since 2006. For more information see its website.

We seek Safe Harbor.